Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Bendell on a Study of Onartuzumab Plus Bevacizumab for mCRC

May 13th 2014

Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).

TAS-102 Extends Survival in Heavily Pretreated Colorectal Cancer

May 12th 2014

Treatment with the investigational oral agent TAS-102 significantly improved overall survival in a phase III trial for patients with heavily pretreated metastatic colorectal cancer.

FDA Panel Unanimously Recommends New DNA Stool Test

March 27th 2014

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

FDA Panel Narrowly Supports New CRC Blood Test

March 27th 2014

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

Dr. Bordonaro on the Treatment of Advanced CRC

March 13th 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Dr. Peeters on the Future of Colorectal Cancer

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Final Thoughts on the Treatment of mCRC

February 26th 2014

Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014

Third-Line Treatment Options for mCRC

February 26th 2014

First- and Second-Line Treatment of mCRC in Specific Populations

February 26th 2014

Current Trends in the Treatment of CRC

February 26th 2014

Tumor Profiling in Patients With mCRC

February 26th 2014

New Therapies in Development for mCRC

February 26th 2014

Role of the VEGF Inhibitor Aflibercept in mCRC

February 26th 2014

Role of the Multikinase Inhibitor Regorafenib in mCRC

February 26th 2014

Considerations When Selecting an EGFR Inhibitor in mCRC

February 26th 2014

First- and Later-line Use of Panitumumab in mCRC

February 26th 2014

Treatment of Unresectable RAS Wild-type Metastatic CRC

February 26th 2014

Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014